Brentuximab vedotin is both active and well tolerated in cutaneous T-cell lymphoma and lymphatoid papulosis, a new study published online ahead of print in the Journal of Clinical Oncology has shown.

Brentuximab vedotin is a CD30-directed antibody-drug conjugate approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with Hodgkin lymphoma and systemic anaplastic large cell lymphoma.

For the open-label phase II study, researchers enrolled 48 patients with CD30+ lymphoproliferative disorders or mycosis fungoides. All patients received brentuximab vedotin 1.8 mg/kg intravenously every 21 days.

Results showed an overall response rate of 73% (95% CI: 60, 86) and a complete response rate of 35% (95% CI: 22, 49) among the 48 evaluable patients.


Continue Reading

Of the 28 patients with mycosis fungoides, 54% (95% CI: 331, 59) responded to brentuximab vedotin treatment, independent of CD30 expression.

Researchers also found that all patients with primary cutaneous anaplastic T-cell lymphomas and lymphomatoid papulosis responded to treatment with a median duration of response of 26 weeks.

RELATED: Use of Radiotherapy After Chemo for Lymphoma Declining

In regard to safety, 65% of patients experienced grade 1 to 2 peripheral neuropathy, but resolved in 45% of those who reported it in a median of 41.5 weeks. Grade 3 to 4 adverse events included neutropenia, nausea, and chest pain.

Preliminary findings were presented at the 55th Annual Meeting of the American Society of Hematology in New Orleans, LA, in 2013.

Reference

  1. Duvic M, Tetzlaff MT, Gangar P, et al. Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis. J Clin Oncol. 2015. [epub ahead of print]. doi: 10.1200/JCO.2014.60.3787.